Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of the Virus, Pharmacodynamics, Immunogenicity, and Antitumor Activity of GC001 Oncolytic Vaccinia Virus Injection in Patient With Advanced Solid Tumors.

NCT06508307 is registered in ClinicalTrials.gov with GONGCHU Biotechnology Co., Ltd as lead sponsor.

NCT NCT06508307
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06508307 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I Study Evaluating the Safety, Tolerability, Biodistribution and Shedding of the Virus, Pharmacodynamics, Immunogenicity, and Antitumor Activity of GC001 Oncolytic Vaccinia Virus Injection in Patient With Advanced Solid Tumors.
Lead sponsor
GONGCHU Biotechnology Co., Ltd
Phase
Phase 1
Overall status
Recruiting
Start date
April 26, 2023
Completion date
June 30, 2026
Enrollment
21 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer, cervical cancer, colon cancer, gastric cancer, hepatocellular carcinoma, lung cancer, ovarian cancer, pancreatic cancer, sarcoma